SEHK:1419

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Human Health Holdings

Executive Summary

Human Health Holdings Limited, an investment holding company, provides healthcare services in Hong Kong. More Details


Snowflake Analysis

Adequate balance sheet and fair value.

Share Price & News

How has Human Health Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 1419 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 1419's weekly volatility has decreased from 13% to 6% over the past year.


Market Performance


7 Day Return

1.8%

1419

7.9%

HK Healthcare

5.7%

HK Market


1 Year Return

-62.7%

1419

-11.4%

HK Healthcare

14.3%

HK Market

Return vs Industry: 1419 underperformed the Hong Kong Healthcare industry which returned -11.4% over the past year.

Return vs Market: 1419 underperformed the Hong Kong Market which returned 15.2% over the past year.


Shareholder returns

1419IndustryMarket
7 Day1.8%7.9%5.7%
30 Day-9.7%7.6%13.6%
90 Day-6.7%23.1%19.6%
1 Year-62.7%-62.7%-9.1%-11.4%18.9%14.3%
3 Year-69.9%-71.3%-40.8%-44.6%-2.9%-13.1%
5 Yearn/a-20.5%-28.4%70.9%42.2%

Long-Term Price Volatility Vs. Market

How volatile is Human Health Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Human Health Holdings undervalued compared to its fair value and its price relative to the market?

42.3%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 1419 (HK$0.56) is trading below our estimate of fair value (HK$0.97)

Significantly Below Fair Value: 1419 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 1419 is unprofitable, so we can't compare its PE Ratio to the HK Healthcare industry average.

PE vs Market: 1419 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1419's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1419 is good value based on its PB Ratio (0.8x) compared to the HK Healthcare industry average (1.4x).


Next Steps

Future Growth

How is Human Health Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

26.3%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Human Health Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Human Health Holdings performed over the past 5 years?

-26.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1419 is currently unprofitable.

Growing Profit Margin: 1419 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 1419 is unprofitable, and losses have increased over the past 5 years at a rate of 26.8% per year.

Accelerating Growth: Unable to compare 1419's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1419 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-9.1%).


Return on Equity

High ROE: 1419 has a negative Return on Equity (-15.59%), as it is currently unprofitable.


Next Steps

Financial Health

How is Human Health Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: 1419's short term assets (HK$192.0M) exceed its short term liabilities (HK$129.7M).

Long Term Liabilities: 1419's short term assets (HK$192.0M) exceed its long term liabilities (HK$39.2M).


Debt to Equity History and Analysis

Debt Level: 1419's debt to equity ratio (6%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if 1419's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: 1419's debt is well covered by operating cash flow (241.1%).

Interest Coverage: Insufficient data to determine if 1419's interest payments on its debt are well covered by EBIT.


Balance Sheet


Next Steps

Dividend

What is Human Health Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 1419's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 1419's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 1419's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1419's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: 1419 is not paying a notable dividend for the Hong Kong market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1419's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

7.3yrs

Average management tenure


CEO

Kin Ping Chan (56 yo)

5.58yrs

Tenure

HK$2,088,000

Compensation

Mr. Kin Ping Chan, JP, serves as the Chairman of the Board at Human Health Holdings Limited and has been its Chief Executive Officer and Executive Director since June 9, 2015. Mr. Chan is a Co-Owner and Di...


CEO Compensation Analysis

Compensation vs Market: Kin Ping's total compensation ($USD269.36K) is about average for companies of similar size in the Hong Kong market ($USD229.97K).

Compensation vs Earnings: Kin Ping's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Kin Ping Chan
Chairman of the Board & CEO5.58yrsHK$2.09m1.8%
HK$ 3.7m
Chui Wan Sat
CFO & Executive Director5.58yrsHK$2.18mno data
Chun Pong Poon
COO & Executive Director5.58yrsHK$1.68m0.13%
HK$ 262.4k
Lai Sheung Pang
Chief Medical Officer & Executive Director5.58yrsHK$2.00mno data
Wai Hong Chan
Head of Gastroenterology & Hepatology Unit13.25yrsno datano data
Chi Wai Hui
Head of Orthopaedics & Traumatology Unit11.25yrsno datano data
Ka Sing Yuen
Head of General Surgery Unit11.08yrsno datano data
Tat Ming Chan
Head of Otorhinolaryngology Unit11yrsno datano data
Siu Keung Seto
Co-Head of Dental Unit5.5yrsno datano data
Wai Man Lau
Co-Head of Dental Unit5.5yrsno datano data
Ching Yan Man
Company Secretary3.58yrsno datano data

7.3yrs

Average Tenure

53yo

Average Age

Experienced Management: 1419's management team is seasoned and experienced (7.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Kin Ping Chan
Chairman of the Board & CEO5.58yrsHK$2.09m1.8%
HK$ 3.7m
Chui Wan Sat
CFO & Executive Director5.58yrsHK$2.18mno data
Chun Pong Poon
COO & Executive Director5.58yrsHK$1.68m0.13%
HK$ 262.4k
Lai Sheung Pang
Chief Medical Officer & Executive Director5.58yrsHK$2.00mno data
Yue Kwong Chan
Independent Non-Executive Director 5yrsHK$180.00kno data
Sun Wing Lui
Independent Non-Executive Director 5yrsHK$180.00kno data
Kar Tim Sin
Independent Non-Executive Director 5yrsHK$180.00kno data
Kin Hung Kwong
Member of Doctor Advisory Board11.42yrsno datano data
Huen Lee
Member of Doctor Advisory Board8.25yrsno datano data

5.6yrs

Average Tenure

53yo

Average Age

Experienced Board: 1419's board of directors are considered experienced (5.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Human Health Holdings Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Human Health Holdings Limited
  • Ticker: 1419
  • Exchange: SEHK
  • Founded: 1997
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: HK$204.958m
  • Shares outstanding: 379.55m
  • Website: https://www.humanhealth.com.hk

Number of Employees


Location

  • Human Health Holdings Limited
  • TAL Building
  • 11th Floor
  • Kowloon
  • Kowloon
  • Hong Kong

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
1419SEHK (The Stock Exchange of Hong Kong Ltd.)YesOrdinary SharesHKHKDApr 2016

Biography

Human Health Holdings Limited, an investment holding company, provides healthcare services in Hong Kong. The company offers general practice services, including general consultation, diagnostics and preven...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/20 10:02
End of Day Share Price2021/01/20 00:00
Earnings2020/06/30
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.